Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine

Leonard Amaral, Joseph Molnar

Research output: Contribution to journalShort survey

18 Citations (Scopus)


Multidrug-resistant tuberculosis (MDRTB) infections that continue to increase in frequency globally have progressed to become extremely drug-resistant tuberculosis (XDRTB). The therapeutic problems associated with MDRTB pale in comparison to those for XDRTB where mortality is high. This mini-review highlights the evidence that supports the use of the phenothiazine neuroleptic thioridazine for the therapy of XDRTB. Although thioridazine does produce some serious side-effects, the poor prognosis associated with an XDRTB infection of a patient that presents with AIDS merits that the use of thioridazine for therapy of XDRTB is seriously considered. A recommended protocol is presented.

Original languageEnglish
Pages (from-to)231-236
Number of pages6
JournalIn Vivo
Issue number2
Publication statusPublished - Mar 1 2012



  • Drug-resistant tuberculosis
  • Multidrug-resistant tuberculosis
  • Phenothiazines
  • Thioridazine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this